Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00064311 · ClinicalTrials.gov registry record · Phase 1

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

A Phase 1 study of Breast Cancer and Lymphoma, sponsored by National Institutes of Health Clinical Center (CC).

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00064311: Completed Phase 1 study of Breast Cancer and Lymphoma, sponsored by National Institutes of Health Clinical Center (CC).

NCT00064311 is a Phase 1 study of Breast Cancer and Lymphoma that has completed, run by National Institutes of Health Clinical Center (CC). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00064311, a Phase 1 study of Breast Cancer and Lymphoma, has completed, sponsored by National Institutes of Health Clinical Center (CC).

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

RATIONALE: Antifungals such as ravuconazole may be effective in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation. PURPOSE: Phase I/II trial to study the effectiveness of ravuconazole in preventing fungal infections in patients undergoing allogeneic stem cell transplantation.

Conditions Studied

Breast Cancer Lymphoma Leukemia Myelodysplastic Syndromes Neuroblastoma Multiple Myeloma and Plasma Cell Neoplasm Infection Chronic Myeloproliferative Disorders Myelodysplastic/Myeloproliferative Neoplasms Gestational Trophoblastic Tumor

Interventions

  • DRUG ravuconazole

Study Locations (1)

Maryland

  • Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda

Trial Details

FieldValue
Start Date 2003-06
Est. Completion 2004-09
Phase Phase 1
National Institutes of Health Clinical Center (CC)

338 total trials

What the finished NCT00064311 record still lists

NCT00064311 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which ravuconazole is the first listed.

NCT00064311 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00064311 about?

NCT00064311 is a clinical study titled "Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation". RATIONALE: Antifungals such as ravuconazole may be effective in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation. PURPOSE: Phase I/II trial to study the effectiveness of ravuconazole in preventing fungal infections in patients undergoing allogeneic stem...

What is the current status of trial NCT00064311?

This trial is currently completed. It is a Phase 1 study. The study started on 2003-06. Estimated completion is 2004-09.

What conditions does trial NCT00064311 study?

This clinical trial studies the following conditions: Breast Cancer, Lymphoma, Leukemia, Myelodysplastic Syndromes, Neuroblastoma.

What interventions are being tested in trial NCT00064311?

The interventions under investigation include: ravuconazole (DRUG).

Who is sponsoring clinical trial NCT00064311?

This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00064311 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00064311, the US trial registry maintained by the National Library of Medicine. NCT00064311 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.